Journal of Medical Physics
 Home | Search | Ahead of print | Current Issue | Archives | Instructions | Subscription | Login  The official journal of AMPI, IOMP and AFOMP      
 Users online: 534  Home  EMail this page Print this page Decrease font size Default font size Increase font size 
Year : 2012  |  Volume : 37  |  Issue : 4  |  Page : 235-239

Radiotherapy pre-treatment dose validation: A second verification of monitor units (MU) with a commercial software

Department of Radiotherapy, National Oncology Center, Royal Hospital, Muscat, Sultanate of Oman

Correspondence Address:
Ramamoorthy Ravichandran
Medical Physics Unit, Department of Radiotherapy, National Oncology Center, Royal Hospital, PB 1331, PC 111, Muscat
Sultanate of Oman
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-6203.103610

Rights and Permissions

Inversely planned intensity-modulated radiotherapy (IMRT) and stereotactic small field radiotherapy should be verified before treatment execution. A second verification is carried out for planned treatments in IMRT and 3D conformal radiotherapy (3D-CRT) using a monitor verification commercial dose calculation management software (DCMS). For the same reference point the ion-chamber measured doses are compared for IMRT plans. DCMS (Diamond) computes dose based on modified Clarkson integration, accounting for multi-leaf collimators (MLC) transmission and measured collimator scatter factors. DCMS was validated with treatment planning system (TPS) (Eclipse 6.5 Version, Varian, USA) separately. Treatment plans computed from TPS are exported to DCMS using DICOM interface. Doses are re-calculated at selected points for fields delivered to IMRT phantom (IBA Scanditronix Wellhofer) in high-energy linac (Clinac 2300 CD, Varian). Doses measured at central axis, for the same points using CC13 (0.13 cc) ion chamber with Dose 1 Electrometer (Scanditronix Wellhofer) are compared with calculated data on DCMS and TPS. The data of 53 IMRT patients with fields ranging from 5 to 9 are reported. The computed dose for selected monitor units (MU) by Diamond showed good agreement with planned doses by TPS. DCMS dose prediction matched well in 3D-CRT forward plans (0.8 ± 1.3%, n = 37) and in IMRT inverse plans (−0.1 ± 2.2%, n = 37). Ion chamber measurements agreed well with Eclipse planned doses (−2.1 ± 2.0%, n = 53) and re-calculated DCMS doses (−1.5 ± 2.6%, n = 37) in phantom. DCMS dose validation is in reasonable agreement with TPS. DCMS calculations corroborate well with ionometric measured doses in most of the treatment plans.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded206    
    Comments [Add]    

Recommend this journal